期刊文献+

乳腺癌组织中耐药蛋白的表达及化疗耐药性的相关性研究 被引量:7

EXPRESSION AND CHEMORESISTANCE-RELATED RESEARCH OF RESISTANCE-RELATED PROTEIN IN BREAST CANCER
下载PDF
导出
摘要 目的:探讨三种耐药蛋白GST-π,P-gp,Topo-Ⅱ在乳腺癌组织中的表达,比较分析三种耐药相关基因蛋白在不同临床特点的乳腺癌和不同分子分型乳腺癌组织中的表达差别,为临床治疗提供依据。方法:采用免疫组织化学HRP法检测60例Luminal A型;60例Her-2(+)(其中含有Her-2阳性的Luminal B型);46例三阴性乳腺癌组织中GST-π,P-gp和Topo-Ⅱ的表达,并结合病理特点进行分析。结果:GST-π、P-gp、Topo-II的表达与病人年龄、肿瘤大小无关。GST-π、P-gp在"Her-2(+)组"及"三阴组"表达率高于"LuminalA组"的表达率,呈正相关(P<0.05)。GST-π的表达与组织学分级、激素受体表达、乳腺癌的分子分型有关,有统计学意义(P<0.05)。P-gp的表达与淋巴结转移与否、HER-2表达状况、乳腺癌的分子分型呈正相关(P<0.05);Topo-II与淋巴结转移与否呈正相关(P<0.05)。结论:GST-π、P-gp高表达是乳腺癌多药耐药发生的高危因素;Topo-II其表达量的高低与化疗药物作用正相关,与肿瘤的恶性程度正相关。 Objective: Explore the three resistance protein GST-π, P-gp, Topo-Ⅱ expression in breast cancer, comparative analysis of a variety of resistance-associated protein in the different clinical characteristics of breast cancer and different molecular classification of breast cancer tissue expression of differences, to provide a basis for clinical treatment. Methods: Immunohistochemistry was used to HRP was detected 60 cases of luminal A subtype;60 cases of Her-2 (+) (containing Her-2 positive Luminal B subtype) ;46 cases of triple negative breast cancer tissue,the expression of GST-π,P-gp and Topo-Ⅱ, combined with the pathological features were analyzed. Results:The expression of GST-π, P-gp,Topo-Ⅱ with patient age, tumor size, express no statistical significance. The expression of GST-π,P-gp in the Her-2(+) group and the triple negative group expression is higher than Luminal A subtype rates was positively correlated (P〈0.05). The expression of GST-π and histological grade, hormone receptor expression, and molecular classification of breast cancer was positively correlated (P〈 0.05 ). The expression of P-gp and lymph node metastasis, HER-2 expression, molecular classification of breast cancer was positively correlated ( P 〈 0.05 ) ; The expression of Topo - Ⅱ and lymph node metastasis is related to statistically significant ( P 〈 0.05 ). Conclusion: GST - π, P - gp was highly expressed in breast cancer more than to be the resistance occurring risk factors;The expression level of Topo-Ⅱ with the chemotherapy drugs was positively correlated, related to a positive correlation with the degree of malignancy.
出处 《内蒙古医科大学学报》 2014年第3期211-216,共6页 Journal of Inner Mongolia Medical University
基金 内蒙古自治区科技计划项目(20100510)
关键词 耐药蛋白 乳腺癌 分子分型 免疫组织化学 耐药性 resistance - related protein breast cancer molecular classification immunohisto - chemistry resistance
  • 相关文献

参考文献15

  • 1Jemal A. , Siegel R. , Ward E. , et al. Cancer statistics, 2007 ; CA Cancer J Clin,57:43-66,2007.
  • 2Lin Y, Lin S,Watson M, et al. A gene expression signature that predicts the therapeutic response of the basal- like breast cancer to neoadjuvant chemotherapy [ J ]. Breast Cancer Res Treat,2010 ; 123 ( 3 ) :691-699.
  • 3Bussolati G, Sapion A. mucinous carcinoma and carcinomas with sigmet- ring - cell differentiation. In : lakhani SR , Ellis 01, Schnitt S J, et al. Who classification of tumors of the breast [ M ]. Lyon : Editors IARC Press, 2012 : 60-61.
  • 4Castaneda CA, AndrOs E, Barcena C, et al. Behaviour of breast cancer molecular subtypes through tumor progression [J]. Clin Transl 0ncol,2012;14(6) :481-485.
  • 5邵志敏.乳腺肿瘤学[M].上海:上海科学技术出版社,2005.45-47.
  • 6崔洁,刘新兰,王宁菊.三种耐药相关基因及其蛋白在乳腺癌组织中的表达和意义[J].中华检验医学杂志,2010,33(12):1164-1170. 被引量:7
  • 7Gabrielle R, Adedayo O, Jessical E, et al. Adjuvant therapy for her- 2breast cancer: practice, Perception, And toxicity [ J]. Breast Cancer Res Treat,2012 ;131:713-721.
  • 8Antonis V, Davide M, Nikolaos P, et al. Trastuzumab combined to neoadjuvant chemotherapy in patients with her2-positive breast cancer:A systematic review and meta -analysis [ J ]. The Breast ,2011 ;20:485-490.
  • 9林镇和,陈炬莹,陈晓耕.p53、Ki-67、TopoⅡ、GST、P170对三阴乳腺癌预后的相关性分析[J].实用肿瘤学杂志,2010,24(2):138-143. 被引量:7
  • 10Kuo MT. Redox regulation of multidrug resistance in cancer chemotherapy : molecular mechanisms and therapeutic opportunities [ J ]. Antioxid Redox Signal, 2009;11(1) :99-133.

二级参考文献22

  • 1桂贤,刘会敏.肿瘤多药耐药发生机制的研究进展[J].上海医学,2005,28(2):161-164. 被引量:25
  • 2Pharoah PD,Day NE,Caldas C.Somatic mutations in the p53 gene and prognosis in breast cancer:a meta-analysis[J].Br J Cancer,1999,80(12):1968-1973.
  • 3Soussi T,Beroud C.Assessing TP53 status in human tumours to evaluate clinical outcome[J].Nat Rev Cancer,2001,1(3):233-240.
  • 4Fuji H,Tanjgawa N,Muraoda R,et al.Detection of P-glycoprotein by now cytometry[J].Anticancer Res,1993,13:217.
  • 5Hall PA,Levison DA,Woods AL,et al.Proliferating cell nuclear antigen(PCNA)immunoloealization in parafin sections:an index of cell proliferation with evidence of deregulated expression in some neoplasms[J].J Pathol,1990,162(4):285-294.
  • 6Huang J,Tan PH,Thiyagarajan J,et al.Prognostic significance of glutathione-s-transferases-pi in invasive breast cancer[J].Mod Pathol,2003,16(6):558-565.
  • 7Haffty BG,Yang Q,Reiss M,et al.Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer[J].J Clin.Oncol,2006,24:5652-5657.
  • 8Rakha EA,El-Sayed ME,Green AR,et al.Prognostic markers in triple-negative breast cancer[J].Cancer,2007,109:25-32.
  • 9Tischkowitz M,Brunet JS,Begin LR,et al.Use of immunohistochemical markers can refine prognosis in triple negative breast cancer[J].BMC Cancer,2007,7(134):1-11.
  • 10Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics[J].CA Cancer J Clin,2005,55(2):74-108.

共引文献16

同被引文献62

  • 1侯宝洲,孙剑经.β-catenin、TopoⅡ和ki67在恶性肿瘤中的作用研究进展[J].河北北方学院学报(自然科学版),2013,29(5):109-113. 被引量:3
  • 2周波,杨德启,乔新民,佟富中,曹迎明,刘鹏,刘宏军.可手术乳腺癌新辅助化疗后保乳手术的可行性研究[J].中华医学杂志,2005,85(11):769-772. 被引量:13
  • 3Gen-Sheng Feng.Shp2-mediated molecular signaling in control of embryonic stem cell self-renewal and differentiation[J].Cell Research,2007,17(1):37-41. 被引量:6
  • 4Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treat- ment of women with early breast cancer: highllghts of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 [ J]. Ann Oncol,2013,2g (9) :2206 - 2223.
  • 5Perou CM,Sorlie T, Eisen MB,et al. Molecular portraits of human breast tumors[ J]. Nature ,2000,406 ( 6797 ) :747 - 752.
  • 6Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes[ J]. J Clin 0ncol,2009, 27(8) :1160 - 1167.
  • 7Rocque G,Onitilo A, Engel J,et al. Adjuvant therapy for HER2 + breast cancer:practice,perception, and toxicity [ J ]. Breast Cancer Res Treat ,2012,131 ( 2 ) :713 - 721.
  • 8Valachis A, Mauri D, Polyzos NP, et al. Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2 -positive breast cancer: a systematic review and meta-analysis[ J]. Breast,2011,20(6) :485 -490.
  • 9Lehmann BD,Pietenpol JA.Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes[J].J Pathol,2014,232(2):142-150.
  • 10Galak.Chandarlapaty S.Molecular Pathways:HER3 Targeted Therapy[J].Clin Cancer Res,2014,20:14 10-1 416.

引证文献7

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部